NASDAQ
CELU
Last Price
US $0.76
KEY FIGURES
MKT CAP
$18.2M
EPS
TTM
$-3.58
PEG
TTM
N/M
P/E
TTM
N/M
P/S
TTM
0.73x
YIELD
0.00%
GROWTH
Revenue Y/Y
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Celularity Inc. cash flow to debt ratio of -32.41% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Celularity Inc.'s free cash flow has decreased 101.98% from $-6.56M last year to $-13.25M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Celularity Inc.'s debt to equity ratio is -1.07, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Healthy debt to equity ratio development.
Celularity Inc.'s debt to equity ratio is -1.07, signaling that the company spent its equity and risk bankruptcy.
Financial risk - Net debt/EBITDA.
Celularity Inc. has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Celularity Inc.'s interest coverage ratio is -9.08, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial risk - Profit margin growth.
Celularity Inc.'s profit margin has decreased (223.52%) in the last year from -106.77% to -345.44%, signaling decreasing performance
Financial risk - Short term assets vs short term liabilities.
Celularity Inc.'s short-term liabilities of $80.76M exceed its short-term assets of $12.32M, signaling financial risk
Decreasing performance - ROA.
Celularity Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Increasing performance - Absolute return on equity.
Celularity Inc.'s return on equity of 411.46%, is higher than 15.00%, indicating good performance
Decreasing performance - Earnings quality.
Celularity Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Celularity Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Celularity Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Celularity Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Celularity Inc.'s yearly earnings has decreased 58.57% since last year from $-57.89M to $-91.80M, signaling decreasing performance
Decreasing performance - Healthy revenue growth.
Celularity Inc.'s yearly revenue has decreased -51.03% since last year from $54.22M to $26.55M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -151.11% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Celularity Inc.'s 3-year revenue CAGR of 13.88% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Celularity Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Celularity Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Celularity Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Celularity Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Celularity Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Celularity Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Celularity Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Celularity Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails
Undervalued - P/S ratio.
Celularity Inc. has a price-to-sales ratio of 0.73x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
411.46%
Return on equity
ROIC: -151.11%
Valuation History
-0.21X
Price to Earnings
EV/EBITDA: -0.68X
Cash flow
Profit margin
13.21%
(FY vs FY)
EBITDA Y/Y
21.12%
(FY vs FY)
Cash flow Y/Y
47.02%
(FY vs FY)
Cash Flow (DCF)
Fair Value
Market $0.76
—
Default assumptions
EBITDA Multiple
Fair Value
Market $0.76
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.